Single-Dose Rituximab for Recurrent Glomerulonephritis Post-Renal Transplant
- 24 January 2015
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 41 (1) , 37-47
Abstract
Background/Aims: Post-renal transplant recurrent glomerulonephritis (GN) contributes to allograft loss. Rituximab treatment has been used in a multidose strategy with variable efficacy and toxicity. We investigated a novel single-dose approach. Methods: A single center, retrospective, cohort study was conducted between January 1998 and April 2012 among renal allograft recipients with recurrent GN treated with rituximab (cases) or without (controls). The primary outcome was complete response (CR, urine protein/creatinine ratio (UP/C) 50% reduction in UP/C), response relapse, treatment-response by GN type, acute rejection incidence, time to graft loss, and infection incidence. Results: The median dose of rituximab was 200 mg per patient. Of 20 rituximab cases and 13 controls, CR was achieved in eight (40%) versus four (31%), respectively (p = 0.72). Three subjects in each group achieved PR (p = 0.66). Response relapse was similar between the two groups (p = 0.47). Significantly more subjects with recurrent membranous nephropathy (MN) achieved CR with rituximab treatment (p = 0.029). Acute rejection was lower in the rituximab group versus controls (n = 0 vs. 4; p = 0.046). The mean time to graft loss was much later in the rituximab group (35 months, (95% CI 33-37)) versus controls (29 months, (95% CI 24-35)) at 36 months (p = 0.04). There was no infection increase in rituximab-treated subjects (p = 0.16). Conclusion: Single-dose rituximab for treatment of recurrent GN was associated with less subsequent rejection and longer time to graft loss without increased infection, but was no more effective than regimens not using rituximab at 36-months except those with recurrent membranous GN.Keywords
This publication has 27 references indexed in Scilit:
- Combination Treatment With Plasmapheresis and Rituximab for Recurrent Focal Segmental Glomerulosclerosis After Renal TransplantationArtificial Organs, 2011
- Effect of Single-Dose Rituximab on Primary Glomerular DiseasesNephron Clinical Practice, 2010
- Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximabTransplant International, 2010
- Beneficial Effect of Rituximab in the Treatment of Recurrent Idiopathic Membranous Nephropathy after Kidney TransplantationClinical Journal of the American Society of Nephrology, 2010
- Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant PatientsAmerican Journal of Transplantation, 2009
- Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipientsTransplant International, 2009
- Rituximab Failed to Improve Nephrotic Syndrome in Renal Transplant Patients With Recurrent Focal Segmental GlomerulosclerosisAmerican Journal of Transplantation, 2008
- Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosisTransplant International, 2007
- Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximabTransplant International, 2006
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999